Treatment of acute deep venous thrombosis and pulmonary embolism: Use of low molecular weight heparin

Seminars in Respiratory and Critical Care Medicine

Volumn 21, Issue 6, 2000, Pages 547-553

  Tapson, V F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Deep venous thrombosis; Heparin; Low molecular weight heparin; Pulmonary embolism

Indexed keywords

ARDEPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LUNG EMBOLISM; OUTPATIENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW;

EID: 0034525697     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-13191     Document Type: Review

References (47)

1. Antithrombotic therapy for venous thromboembolic disease
2. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety
3. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis
4. Is embolic risk conditioned by location of deep venous thrombosis?
5. The weight-based heparin dosing nomogram compared with a "standard care" nomogram
6. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis
7. Optimal therapeutic level of heparin therapy in patients with venous thrombosis
8. Safety of low-molecular-weight heparin in pregnancy: A systematic review
9. Production and chemical processing of low molecular weight heparins
10. Preclinical differentiation of low molecular weight heparins
11. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis
12. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): Results of a double-blind randomized study
13. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT)
14. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis
15. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
16. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216)
17. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
18. Dose adjusted heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
19. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis
20. Treatment of established venous thromboembolism with enoxaparin: Preliminary report
21. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal vein thrombosis
22. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the initial treatment of proximal-vein thrombosis
23. Subcutaneous low molecular weight versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial
24. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
25. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
26. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
27. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis
28. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
29. Treatment of deep venous thrombosis with low-molecular-weight heparins: A meta-analysis
30. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis
31. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
32. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
33. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
34. Low molecular-weight heparin in the treatment of patients with venous thromboembolism
35. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: An open randomized pilot study
36. Outpatient treatment of PE with dalteparin
37. A comparison of low molecular-weight-heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis
38. Low molecular-weight-heparin versus heparin for proximal deep vein thrombosis
39. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis
40. Low-molecular-weight heparin compared with unfactionated heparin for treatment of acute DVT: A cost-effectiveness analysis
41. Treatment of proximal vein thrombosis with subcutaneous low-molecular weight heparin vs. intravenous heparin: An economic perspective
42. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
43. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism
44. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread
45. Prevention of venous thromboembolism in cancer patients
46. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
47. Management of venous thromboembolic disease: The impact of low-molecular-weight heparin